Hironori Fukuda

5PUBLICATIONS
61CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 04, 2026
Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker.

|May 07, 2026
Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma.

|Jan 27, 2026
Non-Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors.

Hiroki Ishihara, Yu-Yu Liu, Riu Yamashita

|Jul 08, 2025
EML4-ALK Rearrangement Creates a Distinctive Myeloid Cell-Dominant Immunosuppressive Microenvironment in Lung Cancer.

Kosuke Arai, Yukari Nishito, Hideaki Mizuno

|Jun 28, 2023
Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations.

Kazunori Aoki, Yukari Nishito, Noriko Motoi

Pageof 1

Frequent Collaborators

3 joint publications

Kazunori Aoki

3 joint publications

Makiko Yamashita

3 joint publications

Shigehisa Kitano

2 joint publications

Yukari Nishito